S&P 500 (NYSE:SPY) component Mylan Laboratories, Inc. (NASDAQ:MYL) will unveil its latest earnings on Wednesday, July 27, 2011. Mylan, Inc. is a global pharmaceutical company that develops, licenses, manufactures, markets and distributes pharmaceuticals and active pharmaceutical ingredients.
Mylan Laboratories, Inc. Earnings Preview Cheat Sheet
Wall St. Earnings Expectations: The average estimate of analysts is for profit of 45 cents per share, a rise of 21.6% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved down from 50 cents. Between one and three months ago, the average estimate moved down, but it has been unchanged at 45 cents during the last month. For the year, analysts are projecting net income of $2 per share, a rise of 24.2% from last year.
Past Earnings Performance: The company met estimates last quarter after beating the forecasts in the prior two. In the first quarter, the company reported profit of 44 cents per share versus a mean estimate of net income of 44 cents per share. In the fourth quarter of the last fiscal year, the company beat estimates by 0 cents.
Wall St. Revenue Expectations: On average, analysts predict $1.5 billion in revenue this quarter, a rise of 9.5% from the year ago quarter. Analysts are forecasting total revenue of $6.13 billion for the year, a rise of 12.5% from last year’s revenue of $5.45 billion.
Analyst Ratings: Analysts are bullish on this stock with 13 analysts rating it as a buy, one rating it as a sell and four rating it as a hold.
Revenue has risen the past four quarters. Revenue increased 12.1% to $1.45 billion in first quarter. The figure rose 6.1% in the fourth quarter of the last fiscal year from the year earlier, climbed 7.2% in the third quarter of the last fiscal year from the year-ago quarter and 8% in the second quarter of the last fiscal year.
Competitors to Watch: Pfizer Inc. (NYSE:PFE), Watson Pharmaceuticals, Inc. (NYSE:WPI), Par Pharmaceutical Companies, Inc. (NYSE:PRX), Impax Laboratories, Inc. (NASDAQ:IPXL), Merck & Co., Inc. (NYSE:MRK), Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA), Lannett Company, Inc. (AMEX:LCI), Novartis AG (NYSE:NVS), Forest Laboratories, Inc. (NYSE:FRX), and Taro Pharmaceutical Industries Ltd. (TAROF).
Stock Price Performance: During April 25, 2011 to July 20, 2011, the stock price had fallen $1.63 (-6.5%) from $25.02 to $23.39. The stock price saw one of its best stretches over the last year between June 22, 2011 and July 1, 2011 when shares rose for eight-straight days, rising 9.3% (+$2.12) over that span. It saw one of its worst periods between April 27, 2011 and May 6, 2011 when shares fell for eight-straight days, falling 5.3% (-$1.33) over that span. Shares are up $2.26 (+10.7%) year to date.
(Source: Xignite Financials)